ofatumumab

{
  "id": "MLC-T-ONC-006023",
  "term": "ofatumumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Ofatumumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Ofatumumab may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and HuMax-CD20.",
    "A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development."
  ],
  "synonyms": [
    "Arzerra",
    "HuMax-CD20"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ofatumumab/"
}